Bevicra - Bevacizumab 100 mg Inj

Bevicra 100 mg/4 mL contains bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein involved in abnormal blood-vessel formation. It is widely used in oncology as part of treatment protocols for several cancers, including colorectal, lung, kidney, cervical, and ovarian cancers. Bevacizumab is also utilized in ophthalmic care through specialist-directed applications for certain retinal conditions involving abnormal blood-vessel growth. By inhibiting VEGF activity, it helps restrict the formation of new blood vessels and supports established therapeutic approaches in cancer and ophthalmology.